Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

CATX

AMEX

Perspective Therapeutics (CATX)

0.8578 USD +2.11% vs prior close Nov 9, 2026
Perspective Therapeutics, Inc. price graph
63 sessions
4 0 12 Aug 9 Nov

The line runs 3.28 USD on 12 August through 0.8578 USD on 9 November, on a scale from 0 to 4. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
103.6M USD
EPS, diluted, year to Dec 2025
−1.40 USD
Avg volume
186.4K

as of Nov 9, 2026

Have Perspective Therapeutics (CATX) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Perspective Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 13 Nov 2025.

Form 4, 90 days to 10 Nov 2026, newest reported trade 4 Sep 2026

0buys
7sells
$1.62Mnet sold
0other filings
Have Perspective Therapeutics (CATX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
04 Sep 2026Lantheus Alpha Therapy, LLC10% OwnerSell167,149526K USD
03 Sep 2026Lantheus Alpha Therapy, LLC10% OwnerSell80,783251K USD
02 Sep 2026Lantheus Alpha Therapy, LLC10% OwnerSell42,129131K USD
01 Sep 2026Lantheus Holdings, Inc.10% OwnerSell35,769112K USD
01 Sep 2026Lantheus Alpha Therapy, LLC10% OwnerSell35,769112K USD
31 Aug 2026Lantheus Holdings, Inc.10% OwnerSell78,145246K USD
31 Aug 2026Lantheus Alpha Therapy, LLC10% OwnerSell78,145246K USD
Sold7 open-market sales517,889$1.62M

Which funds hold Perspective Therapeutics (CATX)?

7 of the 45 institutional funds we track reported a Perspective Therapeutics position for the quarter ended 30 Jun 2026 — a combined 46.7M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Perspective Therapeutics (CATX)?
FundPositionSharesValueShares q/q
Millennium ManagementHeld (±25%)4,911,85516.7M USD+21.4%
Citadel AdvisorsHeld (±25%)3,805,73913.0M USD+6.7%
Balyasny Asset ManagementHeld (±25%)3,320,22411.3M USD+10.9%
Two Sigma InvestmentsAdded1,556,4515.3M USD+55.1%
Renaissance TechnologiesNew position59,133202K USD
AQR Capital ManagementHeld (±25%)27,99895K USD+4.8%
Tudor Investment CorpTrimmed18,10662K USD−46.7%

What has been filed or recorded for Perspective Therapeutics (CATX)?

The filings we hold for Perspective Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Perspective Therapeutics (CATX)?
And
13 Oct 2026Fails to deliverShares failed to deliver1,700 shares4K USD notional · 0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver2,146 shares5K USD notional · 0.002% of shares out
30 Sep 2026Fails to deliverShares failed to deliver160,423 shares420K USD notional · 0.141% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.27 USD
30 Sep 2026FinancialsTotal assets365.7M USDat period end
30 Sep 2026FinancialsTotal equity294.7M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.22 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.25 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.40 USD
31 Dec 2025FinancialsNet income−103.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.40 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.35 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.29 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.25 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.23 USD

What do people ask about Perspective Therapeutics (CATX)?

From live data
What did Perspective Therapeutics shares close at?0.8578

Perspective Therapeutics closed at 0.8578 USD on 9 Nov 2026, up 2.11% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Perspective Therapeutics’ market cap?103.6M

Perspective Therapeutics is worth 103.6M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Perspective Therapeutics insiders bought or sold shares recently?7 sales

In the 90 days to 10 Nov 2026, Perspective Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 13 Nov 2025. See Insiders

Which funds own Perspective Therapeutics?7 of 45

7 of the 45 funds we track reported a Perspective Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Citadel Advisors and Balyasny Asset Management. See Funds

When did Perspective Therapeutics last report earnings?−0.27

Perspective Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.27 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings